Read NoL Noteworthy articles right at your iGoogle page, click here! Follow this link to setup Neurobiology of Lipids Noteworthy titles screening right at My Yahoo home page!
Neurobiol Lipids 1, 8 (15 September 2003)
find out how to cite this article

Original Research: 32nd Society for Neuroscience Annual Meeting Proceedings article#:

Alexei R. Koudinov1, 2, CA, Natalia V. Koudinova1 §

1 Russian Academy of Medical Sciences, Moscow, Russian Federation
2 Weizmann Institute of Science, Neurobiology/Biological Regulation, Rehovot, Israel
email: alexeikoudinov@neurobiologyoflipids.org

Accepted for publication 7 November, 2002; Published online: 15 September, 2003 | Article readership
Copyright © 2003 A R Koudinov and N V Koudinova, Licensee Neurobiology of Lipids

Article view and respond options:



Original Abstract 

There is no understanding of the role of amyloid beta protein (Ab) in brain function and Alzheimer's disease. In the present study we attempted to dissect out the role for Ab in the synaptic plasticity in adult rat ex vivo hippocampal slices. The prolonged incubation of slices in our experimental setting preserved basic synaptic physiology but abrogated tetanus induced long term potentiation (LTP). Peptide Ab1-40 rescued LTP while cholesterol synthesis inhibition abolished the restorative action of the peptide. Our observation confirms that Ab protein is a functional player in cholesterol neurochemical pathways and in synaptic structure-functional plasticity. The finding also supports our proposed hypothesis that the change in Ab biochemistry in Alzheimer's disease is a functional phenomenon aiming to compensate impaired cholesterol dynamics and associated neurotransmission and synaptic plasticity failure.


"The half-century of lipophobia in the United States maybe abating with some return of sanity on the discussion of health and dietary fat [1]. The youngesy victims of this collective, decades long madness are those infants deprived for one reason or another of breast milk. They are unable to speak for themselves at a time of greatest need for cholesterol during growth, the most critical period of myelination of central and peripheral nervous system, formation of bone and bile, and of every, steroid hormone. Some of the commercial formulas they are fed contain only 1 or 2 mg of cholesterol per 100 g edible portion contrasted with almost 14 mg in breast milk. One can only hope that the confidence in their endogenous ability to synthesize sufficient amounts of cholesterol is not misplaced" [source: Ref. 2].


See acknowledgement.


Nowadays an increasing number of scientific papers implicates cholesterol in Alzheimer’s disease (AD)[3WEB+, 4WEB+, 5WEB+]. Directed by the amyloid dogma of AD research these articles discuss an involvement of cholesterol in AD pathogenesis mostly through the modulation of amyloid b protein (Ab) manufacturing and deposition. In our recent contribution we proposed an alternative reasoning that cholesterol homeostasis biological misregulation itself has a key role for synaptic plasticity impairment, neuronal degeneration and is the primary cause for several AD hallmarks not limited to brain amyloid [5WEB+]. We also proposed that the change in Ab neurochemistry in the disease represents physiological mechanism aiming to compensate impaired neural cholesterol dynamics and associated neurotransmission and synaptic plasticity failure [3, 4, 5].

Our recent study demonstrated that rats fed a cholesterol diet possess impaired hippocampal long-term potentiation (LTP), spatial behavior, Alzheimer’s-like brain amyloid and increased neural synthesis of cholesterol and phospholipids [5WEB+, 6]. Acute modulation of cholesterol dynamics (particularly, an increase of cholesterol efflux that models an inability of tissue to redistribute cholesterol and other lipids via lipoprotein (LP) transport) in the hippocampal slices injured both neurotransmission and synaptic plasticity [3, 7], caused disruption of neurofilament and increase of PFH-like tau phosphorylation (reproduced in several studies, see Refs. 3, 5 for citations' details), but preserved the pattern of Ab immunofluorescence [3].

Except of the above reports [3, 5], there were no other study that would examine interrelation of brain cholesterol turnover and Ab metabolism with respect to synaptic plasticity, deficit which represents the major Alzheimer’s functional abnormality. In the present study we evaluated the effect of Ab on hippocampal LTP and attempted to test its dependency on hippocampal cholesterol synthesis (see Supplement below for additional background information, also see further reading suggestion).


All experimental procedures were previously reported in details [3WEB+, 7, 8, 9]. Briefly, brains from adult albino Wistar rats (3-4 months, 300-380g) were rapidly removed and placed into cold (20C) artificial CSF (ACSF). Transverse hippocampal slices  (400 m) were prepared with a McIlwain tissue slicer within 4 min of an animal decapitation. After standard recreating incubation at room temperature for 1.5 h in ACSF, slices were subjected to pharmacological treatment (for 18-24 hrs) with the human peptide Ab1-40 (0 and 0.33 mg/ml [83 nM] in ACSF, see Ref. 3) and 0.3 mM mevinolin [7, 10, 11], followed by washing for 3 min (5x) in ACSF and extracellular field recording of evoked postsynaptic potentials (fEPSP) in stratum radiatum of CA1. Electrophysiological recording was performed as described [3, 5, 8]. The tetanic stimulation was delivered at the stimulus intensity that yielded double (compared to baseline responses) EPSP amplitude. The input-stimulus/output-response (I/O) relationship and LTP were expressed as a fEPSP amplitude and slope change versus stimulus intensity and time, respectively. In selected experiments hippocampal slices were subjected to metabolic labeling with [14C]acetate to evaluate the synthesis of cholesterol and phospholipids [3]. The data are presented as mean±SEM. Nonparametric Mann-Whitney signed rank test was used for determining significant differences between experimental values. A probability of 0.05 (one-tailed) or less was accepted as statistically significant.


Prolonged incubation of slices (for 21+ hours) in our experimental condition did not affect basic synaptic physiology (Fig. 1A, inset), but adsorbed the ability of slices to induce/maintain LTP in CA1 area of the hippocampus; an initial post-potentiation level reached 135.2±20.53 % and fell down to 120±11.48 % and 113.0±34.6 % in 3 min and 20 min after the tetanic stimulation (Fig. 1A), compared to 229.4±5.1 %, 163.5±6.1 % and 161.4±6.1 % for the slices maintained in vitro for 6-8 hrs (n = 6 slices, P = 0.0011, P = 0.007 and P = 0.0023, respectively, Ref. 3). The incubation of slices with the peptide Ab1-40, however, resulted in recovery of LTP. After the incubation with Ab (83 nM) initial postpotentiation level reached 205.3±47.43%. At 3 and 20 min after tetanic stimulus the potentiation levels were 190.6±21.43% and 183.1±49.44%, respectively (Fig. 1A). Slices incubated with Ab therefore expressed statistical difference with the slices subjected to 21+ hrs of in vitro maintenance without Ab (n=6 slices, P=0.019, P=0.0048 and P=0.033, respectively). Ab thus reversed the LTP impairment of 21+ hrs slices and made it statistically not different from the slices maintained in vitro for 6-8 hrs only (n=6 slices, P=0.1286, P=0.2317 and P=0.3939 for the fEPSP slopes recorded immediately after the tetanic stimulation and in 3 min and in 20 min post-tetanus, respectively). The treatment of slices with both Ab and mevinolin abolished the restoration of LTP by Ab, and reversed the fEPSP waveforms back to the condition of the prolonged incubation with no Ab (Fig. 1D).
Figure 1



Note: you may need to resize your browser window for better figure view

A, Field excitatory postsynaptic potentials (fEPSPs) recorded from a single site in stratum radiatum of CA1 (C) under the condition of the prolonged incubation of slices without the peptide Ab1-40 (Control) or in the presence of the peptide (Ab) are presented as normalized slopes versus time to yield LTP charts. Ab peptide reversed the impairment of the LTP, a characteristic of synaptic plasticity, in slices subjected to 21+ hrs of in vitro maintenance, and made it statistically not different from the slices maintained for 6-8 hrs only (see text). Inset (I/O maximum) illustrates the maximum values of the input-stimulus/output-response (I/O) curves (indicative of basic synaptic physiology) that show no statistical differences (n=6, P<0.05, one-tailed) between slices maintained for a prolonged time with Ab or without the peptide. D, Representative fEPSPs at the bottom right show that statin mevinolin, a cholesterol synthesis inhibitor (see Scheme 1 for details) abolishes LTP restored by Ab (see text below for discussion details). The presented waveforms are recorded during the baseline stimulation (1), immediately after the tetanic stimulus (2), as well as three (3) and twenty (4) minutes thereafter. Panel B illustrates amino acid sequence differences between rat and used in the study human Ab1-40. Dots on the schematic hippocampal slice (Panel C) illustrate positioning of electrodes.

In our study we focused on the role of Ab1-40 in synaptic plasticity under the condition characterized previously with regard to cholesterol and phospholipid status [3, 5]. This condition, however, is different from those used in other reports on the role of Ab in synaptic function and plasticity (see Supplement). Hippocampal slices are characterized by the basal efflux of lipoprotein cholesterol (4.0±1.23% of the hippocampal cholesterol in 6 hrs, see Ref. 3). This efflux rate in 18 hours could yield the removal of ~12 % hippocampal cholesterol. Such loss of cholesterol in the medium is compatible with the preservation of the basic synaptic physiology but may explain the impairment of LTP in slices [3, 7] subjected to prolonged incubation in the medium in the absence of the external cholesterol donor [12]. On the other hand, peptide Ab1-40 increases cholesterol synthesis (~145% above the control value in 21 hrs) and is capable to enhance the uptake of cholesterol (132.5±11.25% above the control in 21 hrs) by the hippocampal slices (see Ref. 3 for experimental details and related discussion). Thus, the restoration of the hippocampal LTP by the peptide Ab1-40 could be caused by replenishment of hippocampal cholesterol to the level equal or exceeding the loss of lipoprotein cholesterol during the prolonged incubation of the slices [3]. Additional support for restoration of LTP by Ab-mediated biological regulation of the hippocampal cholesterol supply comes from the inhibition of Ab effect by mevinolin. Mevinolin is a member of a group of drugs, called statins, which inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an enzyme that catalyzes rate-limiting reaction in cholesterol biosynthesis. The concentration of mevinolin used in this study causes 50% inhibition of HMG-CoA reductase, does not affect nonsterol isoprenoid pathway products (Scheme 1), and was reported to inhibit neuronal cholesterol content to near 50% [7, 10, 11]. Notably, cholesterol synthesis inhibition completely abolished the maintenance and did not significantly affect the induction of the LTP (Fig. 1).
Scheme 1



Note: you may need to resize your browser window for better scheme view

Cholesterol biosynthesis pathway.

Cholesterol biosynthesis can be divided into three major steps: the biosynthesis of mevalonic acid (Step 1), the conversion of mevalonate to squalen (Step 2), and the cyclization of squalen to yield cholesterol (Step 3) [see Ref. 105]. It was shown that the major source of mevalonate in the liver and muscles is Acetyl-CoA and leucine, respectively [105]. Both molecules in a number of enzymatic reactions form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). HMG-CoA then is getting reduced to mevalonic acid. At the second step mevalonate undergoes phosphorylation in the presence of ATP yielding the synthesis of several phosphorylated derivatives. Decarboxylation of one of it (Mevalonate-5-pyrophosphate, not shown, these reactions are detailed in [106]) yields Isopentenyl pyrophosphate, an active isopren. This is a widely distributed in nature molecule that also participates in the synthesis of a number of biochemicals, including natural rubber (cis-1,4-polyisoprene), carotenoids, side chains of ubiquinone, vitamins K and E. Isopentenyl pyrophosphate become enzymatically isomerized into Dimethylallyl pyrophosphate [106]. The following condensation of Dimethylallyl pyrophosphate and  Isopentenyl pyrophosphate yields Geranyl pyrophosphate, a ten carbon molecule. This reaction is associated with the migration of a double bond and the release of one pyrophosphate. Geranyl pyrophosphate interacts with the new molecule of Isopentenyl pyrophosphate and forms Farnesyl pyrophosphate having 15 carbons in its' molecule. Two molecules of Farnesyl pyrophosphate loose their pyrophosphates and interact head-to-head forming a molecule of Squalen having 30 carbons. The formation of Squalen ends the anaerobic phase of cholesterol biosynthesis. The third step (3) is aerobic reducing cyclization of Squalen. This reaction includes double bond migration and yields Lanosterol. The following reactions yield Zimosterol and Desmosterol, an immediate cholesterol precursor: the reduction of Desmosterol yields Cholesterol. The overall reaction for the pathway is presented below:

18CH3CO~S-CoA + 10H+ + 1/2O2  =>  C27H46O + 9CO2 + 18CoA-SH

HMG CoA reductase reaction and statins.

The rate-limiting reaction of the pathway is the synthesis of mevalonate form HMG-CoA. The lower scheme box shows the reaction converting HMG CoA (substrate) to mevalonic acid (product). This reaction is catalyzed by the enzyme HMG-CoA reductase subjected to complex regulatory control, including the feed back inhibition by cholesterol, the pathway product [107]. The inhibition of the HMG-CoA reductase is the target of statins (For a story on statin development see Ref.108). The image at the bottom right presents the structure of  some HMG CoA reductase inhibitors listed in the upper section of the scheme Table. These statins have different substituents at the position X and position Y of the molecule [108]. The chemical structure of fluvastatin, atorvastatin and cerivastatin is available elsewhere [108, 109].

Statins and brain disorders.

Despite the fact that statins are blockbuster drugs [107, 108, 110, 111] the systemic biological consequences of their prolonged use and their effects on brain lipid chemistry, function, plasticity, and neurodegeneration are not understood. This fact is illustrated by an unfortunate death toll associated with the usage of Bayers' Baycol (Cerivastatin that is removed from the market) [112] due to rhabdomyolisis [113], by a statin-induced polyneuropathy [114] and memory loss [115], and by the lack of consensus on a role of statins in Ab biology [116]. 

Statins, however, show promise for Alzheimer's disease prevention and treatment [117, 118, 119, 120, 121], and are the subject of patents [122, 123] and Alzheimer's disease clinical trials [124]. One may wish the understated challenges of statin use [110] will get deserved priority by scientists and funding agencies independent of statin manufactures. 


Amyloid b aids synaptic plasticity by facilitating neural cholesterol dynamics and cholesterol availability

In this report the prolonged maintenance of the adult rat hippocampal slices in a test tube for more then twenty hours preserved synaptic function (input/output characteristics, a measure of basic synaptic function) but abrogated synaptic plasticity (measured as LTP). Ab protein of the 1-40 aminoacids’ molecule length (representing the major form of soluble Ab, a normal human CSF apolipoprotein, see below) rescued LTP while cholesterol synthesis inhibition with a statin reversed the LTP restoration by the peptide.

These results and our past study of the facilitatory role for Ab in the hippocampal cholesterol synthesis and hippocampal cholesterol uptake indicates that Ab may function to compensate impaired cholesterol dynamics and associated break of neuronal and neural networks integrity, neurotransmission, synaptic plasticity, learning and memory [3WEB+, 13, 14, 15]. Such possibility is in accord with the previous data that showed the dependency of neural and synaptic plasticity on the inhibition of cholesterol biosynthesis pathway [7], fine tuned neuronal and astrocytic lipoprotein shuttle [3, 16], its’ receptor machinery [17, 18], and signalling properties [19, 20]. The differential effect of mevinolin co-incubation with Ab on the LTP maintenance, not on the LTP induction (proposed to depend on time demanding cholesterol synthesis and instantly available lipoprotein cholesterol, respectively [3]) indicates that under this experimental condition lipoprotein uptake in hippocampal slices remained functional, possible due to a facilitatory effect of Ab on cholesterol uptake [3, 21]. The stimulation of the neuronal lipoprotein receptors by cholesterol synthesis inhibition (shown for mevinolin in liver of experimental animals [22WEB+]) may also contribute to the preservation of the LTP induction after slice incubation with Ab and mevinolin. The above consideration is in accord with the role for cholesterol proper in the synaptic structure-functional plasticity.

It was previously shown that low dose of Ab1-40 in acute experiment facilitates tetanus-induced LTP [23] and causes the development of slow onset potentiation in the absence of tetanic stimulation [24]. Such effect of Ab1-40 may well be similarly due to an increase of Ab-mediated neuronal cholesterol synthesis and lipoprotein-receptor facilitated cholesterol uptake [3, 17, 18, 23, 24].

Function for Ab in cholesterol metabolism and membrane dynamics

The data presented here imply functional significance for the relation of the neurochemistry of Ab and cholesterol in synaptic plasticity. It is known that Ab modulates neuronal cholesterol esterification [25, 26], uptake (or influx, see Refs. 3, 21), and efflux [27]. These are essential processes that are critical for neural cholesterol intracellular compartmentation and storage, extracellular trafficking, structure-functional membrane dynamics, and lipid raft structure (see Refs. 3, 5 for detailed bibliography). On the other hand, amyloidogenic processing of the amyloid precursor protein (APP) depends on lipid rafts [28]. Ab modulates membrane biophysical properties, particularly cell membrane fluidity [29, 30WEB+] essential for functioning of a number of receptors critically dependent on fine tuned homeostasis of cholesterol and lipid rafts [31, 32, 33, 34, also see Ref. 3WEB+]. Most relevant to the current study may well be Ab-mediated increase of cholesterol synthesis and cholesterol uptake by ex vivo hippocampal slices [3], also reported in PC12 and rat primary neuronal cell cultures and in fetal brain [9].

APP and Ab represent integrated sensor-effector system for neural
cholesterol and membrane dynamics regulation
( detailed in [35] )

Function for Ab in cholesterol metabolism and recent data on the importance of cholesterol compartmentation for Ab generation [28, 36, 37] indicate feedback functional relation between cholesterol and Ab homeostasis. It is additionally supported by a dependency of APP processing and Ab production on membrane lipid rafts, caveolae [28, 38, 39], cholesterol level [40], intracellular storage [37], sterol regulatory binding proteins (SREBP) signalling cascade, particularly the dependency of Ab on the site 2 processing of SREBP and associated inability of cells to upregulate the expression of several enzymes and proteins involved in cholesterol synthesis and turnover [41, 42WEB+]. APP processing and Ab generation also depend on shuttle mechanisms of cholesterol efflux, influx and its’ receptor machinery, and intracellular trafficking [42, 43, 44, 45, 46, 47; not to be mistaken with the discussed earlier separate role for Ab in the processes of cholesterol shuttle, see above). The specific intraneuronal routing of Ab (see Fig. 2 of the original poster presentation that illustrates the intranuclear distribution of exogeneously added Ab1-40 in neuron, also see Ref. 9) and other C-terminal products of APP processing to the nucleus [49] opens the possibility that Ab exerts the action on neuronal cholesterol dynamics by intranuclear modulation of SREBP signalling, liver X receptors (LXR) signalling [ 43WEB+ ], or serving itself a nuclear transcription factor regulating genes encoding enzymes, receptors and (apolipo)proteins involved in cholesterol and other membrane lipids homeostasis. Such complex relation could be of major importance in the CNS for normal synaptic function, plasticity (activity-dependent, developmental and under recovery from injury), neurodegeneration, sporadic and familial (fAD) Alzheimer's disease (detailed in Ref. 35).

A matter-of-fact:
Ab is an essential synaptic protein, NOT neurotoxic junk

Despite a decade long universal publication and grant review bias in favor of the view on Ab as solely neurotoxic (this viewpoint is essential to advance non-validated amyloid hypothesis into clinical application [50WEB+, 51]) current scientific evidence leaves little doubt that Ab serves an essential role at synapse and in synaptic structure-functional plasticity that underlie learning and memory.

Thus it was shown that whereas acute treatment of rat hippocampal slices with low concentrations of bath applied peptide Ab1-40 does not change basal synaptic transmission, there is an increase in tetanus induced LTP [23]. Moreover, Ab1-40 triggered the slow onset long-term potentiation of the NMDA receptor-mediated synaptic currents [24] in the hippocampal slices from young rats, but did not affect the basal AMPA receptor-mediated transmission, resting membrane potential or input resistance of the granule cells. Similar results were presented by Schulz, who showed no effect of Ab1-42 on AMPA currents, but demonstrated the increase of NMDA currents by the peptide [52]. This report proposed that Ab peptides (Ab1-42, Ab1-28 and Ab1-40) increase the probability of LTP under the paradigm that induced little LTP in control slices [52].

Our present study supports previous data on Ab as ‘good’ molecule [23, 24, 52] and further implies an intriguing perspective that Ab protein is a functional player in an activity-dependent cholesterol neurochemical pathways and in synaptic structure-functional plasticity. The finding also corroborates our proposed hypothesis that the change of Ab biochemistry in Alzheimer's disease and related disorders is a functional (but NOT pathologic) compensatory phenomenon aiming to counterbalance impaired cholesterol dynamics and associated neurotransmission and synaptic plasticity.

A role for Ab in neural/synaptic structure-functional plasticity (rather then Ab synaptotoxicity claimed by amyloid neurotoxicity proponents [50]) is additionally supported by several studies by others, particularly, by an increase of synaptic APP with learning capacity in rats [53], by neuronal activity dependent secretion of natural Ab [54], up-regulating a synaptic vesicle protein transcript by Ab1-42 [55], a transient increase of synaptic Ab after the perforant pathway lesioning [56], and the modulation of the APP processing by several neurotransmission systems including cholinergic [57, 58], glutamatergic [59] and serotoninergic [60, in turn shown to depend on membrane cholesterol, Ref. 61] systems. There is a possibility of a bidirectional  modulation between Ab, APP and metabotropic and ionotropic receptor molecules and signalling pathways [62, 63, 44, 64]. Thus, it was shown that the generation of Ab is regulated by the phosphoinositide (PI) pathway, which commonly couples to transmitter receptors, and that Ab peptide is capable to activate the PI pathway in Xenopus oocytes expressing rat brain RNA [64]. Ab also potentiates Ca2+ influx through voltage-sensitive Ca2+ channels [65] and was reported to form calcium-permeable channels in lipid vesicles [66WEB+].

It is important to notice that Ab is a structure-functional apolipoprotein constituent of lipoproteins [67, 68; also see Refs. 3, 69], and that lipoproteins potently inhibit neural toxicity of Ab [70, 71, 72], the fact unfairly missed in articles serving to validate amyloid cascade hypothesis [50, 73, 74]. Ab association with lipoproteins is a property of apparent direct relevance to the role of Ab in the homeostasis of cholesterol and other lipids. Ab-to-lipoprotein association also serves to maintain Ab solubility in the body fluids [29, 75]. The evidence-based synaptic function for Ab and the conceivable lack of the Ab association with lipoproteins in the studies of  oligomeric Ab (also called ADDLs) may exacerbate the lack of the physiological relevance of the oligomers' neurotoxicity [73, 74, 76] and face Alzheimer's field with the question whether amyloid lowering (by vaccination, a secretase modulation or by any other means) could ever be beneficial. This viewpoint is further supported by the “evidence suggesting that loss of endogenous amyloid beta by the pharmacological inhibition of amyloidogenesis results in a severe reduction in the viability of central neurons. In three different neuronal phenotypes, the pharmacological knock-down of amyloidogenic secretase activity resulted in cell death. This study further supports a key physiological role for the enigmatic amyloid beta peptide” [77].

Finally, our latest report indicates a possibility of mistaken identity of lipid-bound soluble monomeric apoAb as plaque or oligomeric Ab in a contemporary Alzheimer’s research [68, 78].


Our data suggest that Ab improves synaptic plasticity by modulating neural cholesterol dynamics [3, 4, 5]. The role of Ab (as a normal human protein) in mediating essential neurochemical pathways, however, is unlikely limited to cholesterol homeostasis. The other pathways can not be excluded and should be studied further in greater details. One such candidate is oxidative stress cascade [79], also shown to be critical for synaptic function and plasticity [80, 81]. The slow onset LTP similarly pharmacologically induced by vitamin E [82] and Ab [24, 52], but impaired in the transgenic mice overexpressing enzyme SOD-1 [80] may be attributed to the lipid antioxidant properties modulation by vitamin E or Ab [79WEB+, 82] and dependency of slow LTP component on a unique molecular mechanism [8, 80, 81, 82].


Essential role for Ab in the mechanisms of synaptic function, plasticity, learning and memory remains to be intriguing and yet not disproved issue.

Such status quo illustrates an inability of Alzheimer’s neuroscience research community to validate amyloid hypothesis despite of intense research and major fields’ research funds allocated to it [4WEB+, 83, 84]. Since anti-amyloid vaccination was halted more then a year ago [4, 84] the question of whether the amyloid hypothesis is true approach for Alzheimer’s disease cure was sounded by many scientists (See Refs. 4WEB+, 85WEB+ for bibliography details). This is especially important because associated with the amyloid dogma competing financial interests and bias apparently retard the development of several other promising approaches [4WEB+,84, 85, 86]. The sad reality became illuminated on March 26, 2003 when Neuron (a major neuroscience journal) published a feature electrophysiological study on APP and Ab synaptic function [54]. This article by Kamenetz et al. was published near three years after it was first submitted and communicated at the Society for Neuroscience Annual Meeting in 2000 [54WEB+].

The three early electrophysiological studies reported Ab-mediated increase of LTP in rat dentate gyrus in in vitro experiments. Thus, it was shown [23] that whereas acute treatment of young rat (70-120 days) hippocampal slices with the low concentration (100-200 nM) of bath applied Ab1-40 did not change basal synaptic transmission, there was an increase in tetanus induced LTP. Moreover, intracellular (100 nM, via the recording pipette) or bath (200 nM) application of Ab1-40 triggered the slow onset potentiation of the NMDA receptor-mediated synaptic currents [24] in the hippocampal slices from young rats (70-120 g weight), and did not affect the basal AMPA receptor-mediated transmission, resting membrane potential or input resistance of the granule cells. It is very unfortunate that the authors oversight these two articles [23, 24] in their later publication on the neurotoxicity of Ab co-authored by a major proponent of the amyloid cascade hypothesis [73]. Similar results (of Ab being a beneficial molecule for synaptic function) were presented by Schulz, who showed no effect of Ab1-42 on AMPA currents, and demonstrated the increase of NMDA currents by the peptide [52]. This report proposed that Ab peptides (Ab1-42, Ab1-28 and Ab1-40) increase the probability of LTP under the paradigm that induced little LTP in control slices [52]. 

Another recent report [86], presented data on Ab1-42 and Ab25-35 inhibition of hippocampal LTP at the concentration of 200nM to 1mM and no effect at 20 nM. This paper, however, employed different from earlier reports [23, 24, 52] protocol (particularly, Sprague-Dawley, not Wistar, rats; 300C recording temperature; stimulus duration of 0.1 msec delivered through sharpened monopolar tungsten electrodes; the decline of bath-applied peptide just prior to the tetanic stimulation), and missed detailed consideration of Ab1-40, also proposed in the article (despite of the lack of experimental data) to inhibit the hippocampal LTP. 

Several other articles reported on Ab infusion into the rat brain followed by electrophysiological [87, 88, 89, 90] or behavioral analysis [91, 92, 93]. The paper of Cullen et al. [87] showed no effect of low concentration of Ab1-40 (0.4 or 3.5 nmol in 5 ml, equal to the I.V. injection of 5 ml of 0.8 mg/ml solution for 3.5 nmol Ab1-40) on the ability to induce LTP in hippocampal slices in vitro, and the delayed (presented 24 and 48 hrs after the injection and not observed 75 min after injection) reduction in the NMDA receptor-mediated responses recorded in vivo. It is important to note that the other study concluded that “NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus” [94]. Another article [88] investigated the effect of intra-cerebroventricular injection of Ab fragments (Ab15-25, Ab25-35 and reverse sequenced Ab35-25) on synaptic transmission and LTP in the CA1 region of the hippocampus in vivo. This report [88] showed an impairment of LTP in a time- (for Ab25-35) and concentration-dependent manner (for Ab25-35 and Ab35-25) but left open the question (as did another recent study, Ref. 90) what would be the effect of Ab1-40 or Ab1-42 in such experimental condition. The authors suggested that injection of Ab1-40 at a dose of 300 pmol/day (the volume of injection, however, remained unclear) for 10-11 days impaired the hippocampal LTP [88]. Another earlier article [89] recorded waveforms in in vitro hippocampal slices at 250C (and not at standard 320C) after the injection of Ab1-40, and expressed LTP as a population spike (PS, but not EPSP) change versus time. Similarly, LTP was expressed as PS change versus time in early article on Ab oligomers [74]. Another earlier report showed no evidence of Ab1-40 accumulation or neurotoxicity after the injection of the peptide into rat hippocampus [91].

Recent behavioral study reported increase of the synaptic b-amyloid precursor protein with learning capacity in rats [53]. Behavioral analyses were characterized by both the absence and the presence of Ab effect on learning and memory in different behavioral experiments [91, 92, 93]. 

Several reports further addressed the puzzling issue of the role of Ab structural properties for neural function. These reports showed that oligomeric [73, 74, 76] and plaque [8, 95, 96, 97] amyloid is capable to impair synaptic or behavioral plasticity, possibly due to breaking the neuronal microcircuitry (see Ref. 8 for discussion details). All cited above studies of oligomeric Ab (also see [98]), while concluding on Ab neurotoxicity, however, miss consideration of the physiological association of Ab with lipoproteins, that potently arrests the peptide toxicity [70, 71, 72]. Such lack of important experimental consideration creates critical flaw of the Ab oligomers studies [73, 74, 76] and must warn all of a well possible lack of the pathophysiological relevance of Ab oligomers [98, 68]. Another recent study suggested age-related impairment of synaptic transmission (but not synaptic plasticity) in transgenic mice that overexpress human APP possessing “Swedish” mutation [99]. Such observation, however, unlikely contradicts the cited above four studies on the role of mature amyloid deposits [8, 95, 96, 97] due to the experimental differences (particularly, the lack of estimation of Ab load at the site of the recording, and employed for recording the stimulus intensity of 20 percent of experimental maximum). 

At present it is impossible to unite cited above in vitro and in vivo electrophysiological and behavioral studies and conclude on the relevance of their experimental conditions to brain physiology and Alzheimer’s disease. The same is true for several most recent articles aiming to clarify the receptor machinery and signalling cascades involved in Ab-mediated modulation of synaptic plasticity [100, 101, 102, 103, 104]. For this reason in the present report we focused on a different (from the above listed studies) experimental condition that we previously characterized with regard to cholesterol and phospholipid metabolism status [3, 5]. 

It is also important to make a note that the majority of articles concluding on Ab as bad molecule oversight critical studies by others on an essential role for Ab in brain neurochemistry and the peptide beneficial effect on synaptic plasticity.


For support and funding itemization see Ref. 3. This research, however, is not funded as a project, and therefore welcomes support. Natalia Koudinova holds visiting scientist status at the Weizmann Institute of Science, Rehovot, Israel. Our research is dedicated to our parents and our children. This article is in memory of N. Koudinova grandmother, Maria Sergeevna (30 Aug. 1914 – 6 Nov. 2002), and A. Koudinov uncle, Boris Fedorovich Kudinov (9 Nov. 1928 – 29 Aug. 2003).

Please note: all links provide no registration free access to documents

1. Taubes G. The soft science of dietary fat. Science. 291, 2536-45 (2001) [ PubMed ]; Correspondence: Ravnskov U, Allen C, Atrens D, et al. Studies of dietary fat and heart disease. Science. 295, 1464-5 (2002) [ PubMed ][ FullText ][ Back2Text ].

2. Opitz JM, Gilbert-Barness E, Ackerman J, Lowichik A. Cholesterol and development: The RSH ("Smith-Lemli-Opitz") syndrome and related conditions. Pediatr Pathol Mol Med. 21, 153-81 (2002) [ PubMed ]. Also see: O'Brien WT, Xu G, Batta A, et al. Developmental sensitivity of associative learning to cholesterol synthesis inhibitors. Behav Brain Res. 129, 141-52 (2002) [ PubMed ][ Back2Text ].

3. Koudinov AR, Koudinova NV. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J. 15, 1858-60 (2001) doi: 10.1096/ fj.00-0815fje [ PubMed ][ FullText ][Meeting presentation slide show][ Authors preface ]; Correspondence: Koudinov AR, Koudinova NV. Cholesterols' role in synapse formation. Science. 295, 2213 (2002) [ PubMed ][ FullText ][ Back2Text ].

4. Koudinov AR, Smith MA, Perry G, Koudinova NV. Alzheimer's disease and amyloid beta protein. Science. (25 June 2002) [ FullText ]. Also see: Koudinov AR. Cholesterol and Alzheimer's: is amyloid beta a cause or consequence of the disease? Science's SAGE KE. (30 July 2003) [ FullText ]; Koudinov AR, Koudinova NV. Alzheimer’s anti-amyloid vaccination and statins: two approaches, one dogma. The time for change. British Medical Journal. (20 March 2002) [ FullText ][ Back2Text ].

5. Koudinov AR, Koudinova NV. Brain cholesterol pathology is the cause of Alzheimer's disease. Clin Med Health Res. (27 Nov 2001) clinmed/2001100005 [ Authors preface ][ FullText ][ AlzForum Hypothesis ]; Correspondence: Koudinov AR, Berezov TT, Koudinova NV. Cholesterol and Alzheimer’s disease: Is there a link? Neurology.58, 1135 (2002) [ PubMed ][ eVersion FullText ][ Back2Text ]. Also see: Wood GW, et al. Symposium Abstracts: Cholesterol and Alzheimer's disease. Neurobiol Lipids. 1, 4 (2002) [ FullText ];  Simmonds MA. The emerging neurobiology of cholesterol. Neurobiol Lipids. 1, 1 (2002) [ FullText ]; Lynch C, Mobley W. Comprehensive theory of Alzheimer's disease. The effects of cholesterol on membrane receptor trafficking. Ann N Y Acad Sci. 924, 104-11 (2000) [ PubMed ][ Back2Text ].

6. Koudinov AR. Dietary cholesterol impairs behavior of lab rats with naive genotype: evidence for the sufficiency of the environmental brain cholesterol modulation to cause sporadic Alzheimer's neurodegeneration phenotype. Soc Neurosci Abstr. Program No. 730.8 (2003) [ Abstract ][ Back2Text ].

7. Matthies H, Schulz S, Hollt V, Krug M. Inhibition by compactin demonstrates a requirement of isoprenoid metabolism for long-term potentiation in rat hippocampal slices. Neuroscience. 79, 341-6 (1997) [ PubMed ][ Back2Text ].

8. Koudinov AR, Berezov TT, Koudinova NV. Amyloid plaque (and not diffuse amyloid) is a condition for neuronal dysfunction. Clin Med Health Res. clinmed/2001110002 (2001) [ FullText ][ Back2Text ].

9. Koudinova NV, Koudinov AR, Yavin E. Alzheimer’s Ab1-40 peptide modulates lipid synthesis in neuronal cultures and intact rat fetal brain under normoxic and oxidative stress conditions. Neurochem Res. 25, 653-60 (2000) [ PubMed ][ Back2Text ].

10. Dansette PM, Jaoen M, Pons C. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins. Exp Toxicol Pathol. 52, 145-8 (2000) [ PubMed ][ Back2Text ].

11. Michikawa M, Yanagisawa K. Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. J Neurochem. 72, 2278-85 (1999) [ PubMed ][ Back2Text ].

12. Pavlov OV, Bobryshev YV, Balabanov YV, Ashwell K. An in vitro study of the effects of lovastatin on human fetal brain cells. Neurotoxicol Teratol. 17, 31-9 (1995) [ PubMed ]. Also see: Bobryshev YV, Pavlov OV, Balabanov YV, Ashwell K. Structural alterations of human immortal astrocytes after inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase by lovastatin. J Submicrosc Cytol Pathol. 27, 435-44 (1995) [ PubMed ][ Back2Text ].

13. Fan Q-W, Yu W, Gong J-S et al. Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cultured neurons. J Neurochem. 80, 178-90 (2002). Erratum in: J Neurochem. 80, 940 (2002) [ PubMed ][ Erratum FullText ][ Back2Text ].

14. Kessler AR, Yehuda S. Learning-induced changes in brain membrane cholesterol and fluidity: implications for brain aging. Int J Neurosci. 28, 73-82 (1985) [ PubMed ]. Also see: Kessler AR, Kessler B, Yehuda S. In vivo modulation of brain cholesterol level and learning performance by a novel plant lipid: indications for interactions between hippocampal-cortical cholesterol and learning. Life Sci. 38, 1185-92 (1986) [ PubMed ]; Xu G, Servatius RJ, Shefer S, et al. Relationship between abnormal cholesterol synthesis and retarded learning in rats. Metabolism Clin. Exp. 47, 878-82 (1998) [ PubMed ][ Back2Text ].

15. O'Brien WT, Xu G, Tint GS, Salen G, Servatius RJ. Blocking cholesterol synthesis impairs acquisition of the classically conditioned eyeblink response. Integr Physiol Behav Sci. 35, 120-31 (2000) [ PubMed ][ Back2Text ].

16. Mauch DH, Nagler K, Schumacher S, et al. CNS Synaptogenesis promoted by glia-derived cholesterol. Science.294, 1354-7 (2001) [ PubMed ]. Also see: Boyles JK, Pitas RE, Wilson ER, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 76, 1501-13 (1985) [ PubMed ]; Correspondence: Koudinov AR. A link between cholesterol, CNS, synapse and brain diseases: is there a need for a reinvention? Neurobiol Lipids. 2, 1 (2003) [FullText ][ Back2Text ].

17. Zhuo M, Holtzman DM, Li Y, et al. Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci. 20, 542-9 (2000) [ PubMed ][ Back2Text ].

18. Champagne D, Rochford J, Poirier J. ApoE and LDL receptor knockout mice display acquisition deficits in the Morris water maze. Soc Neurosci Abstr. 26, 1546 (2000) [ FullText ]; Champagne D, Dupuy JB, Rochford J, Poirier J. Apolipoprotein E knockout mice display procedural deficits in the Morris water maze: analysis of learning strategies in three versions of the task. Neuroscience. 114, 641-54 (2002) [ PubMed ][ Back2Text ].

19. Luque JM, Morante-Oria J, Fairen A. Localization of ApoER2, VLDLR and Dab1 in radial glia: groundwork for a new model of reelin action during cortical development. Brain Res Dev Brain Res. 140, 195-203 (2003) [ PubMed ]. Also see: Herz J. The LDL Receptor Gene Family: (Un)Expected Signal Transducers in the Brain. Neuron. 29, 571-81 (2001) [ PubMed ][ Full Text ]; Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest. 108, 779-84 (2001) [ PubMed ]; Correspondence: Koudinov AR, Koudinova NV. LRP: a cholesterol recruitment checkpoint for neuronal structure-functional plasticity? J Clin Invest. (12 Oct 2001) [FullText]; Koch S, et al. A secreted soluble form of ApoE receptor 2 acts as a dominant-negative receptor and inhibits Reelin signaling. EMBO J.21, 5996-6004 [ PubMed ][ Back2Text ].

20. Quattrocchi CC, Huang C, Niu S, et al. Reelin promotes peripheral synapse elimination and maturation. Science. 301, 649-53 (2003) [ PubMed ][ Back2Text ].

21. Igbavboa U, Avdulov NA, Chochina SV, Sun GY, Wood WG. Amyloid beta peptides and cholesterol dynamics. Neurosci Lett. S55, S25 (2000) [ Back2Text ].

22. Roach PD, Balasubramaniam S, Hirata F, et al. The low-density lipoprotein receptor and cholesterol synthesis are affected differently by dietary cholesterol in the rat. Biochim Biohys Acta. 1170, 165-72 (1993) [ PubMed ]. Also see: Rudling M, Angelin B, Stahle L, et al. Regulation of hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and cholesterol 7alpha-hydroxylase mRNAs in human liver. J Clin Endocrinol Metab. 87, 4307-13 (2002) [ PubMed ][ Back2Text ].

23. Wu J, Anwyl R, Rowan MJ. b-amyloid-(1-40) increases long-term potentiation in rat hippocampus in vitro. Europ J Pharm. 284, R1-R3 (1995) [ PubMed ][ Back2Text ].

24. Wu J, Anwyl R, Rowan MJ. b-amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. NeuroReport.  6, 2409-13 (1995) [ PubMed ][ Back2Text ].

25. Koudinov AR, Koudinova NV, Berezov TT. Alzheimer's peptides Ab1-40 and Ab1-28 inhibit the plasma cholesterol esterification rate. Biochem Mol Biol Inter. 38, 747-52 (1996) [ PubMed ].

26. Liu Y, Peterson DA, Schubert D. Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc Natl Acad Sci USA. 95, 13266-71 (1998) [ PubMed ][ Back2Text ].

27. Michikawa M, Gong JS, Fan QW, Sawamura N, Yanagisawa K. A novel action of Alzheimer's amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release. J Neurosci. 21, 7226-35 (2001) [ PubMed ][ Back2Text ].

28. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer b-amyloid precursor protein depends on lipid rafts. J Cell Biol. 160, 113-23 (2003) [ PubMed ]; Tikkanen R, Icking A, Beicht P, Waneck GL, Volker H. The receptor-bound N-terminal ectodomain of the amyloid precursor protein is associated with membrane rafts. Biol Chem. 383, 1855-64 (2002) [ PubMed ][ Back2Text ].

29. Koudinov AR, Koudinova NV, Berezov TT, Ivanov YD. HDL Phospholipid: a natural inhibitor of Alzheimer's amyloid b fibrillogenesis? Clin Chem Lab Med. 37, 993-4 (1999) [ PubMed ][ Back2Text ].

30. Muller WE, Kirsch C, Eckert GP. Membrane-disordering effects of beta-amyloid peptides. Biochem Soc Trans. 29, 617-23 (2001) [ PubMed ]. Also see: McLaurin J, Chakrabartty A. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J Biol Chem. 271, 26482-9 (1996) [ PubMed ]; Kremer JJ, Sklansky DJ, Murphy RM. Profile of Changes in Lipid Bilayer Structure Caused by b-Amyloid Peptide. Biochemistry,40, 8563 -71 (2001) doi: 10.1021/bi010417x S0006-2960(01)00417-2 [ PubMed ][ Back2Text ]

31. Chochina SV, Avdulov NA, Igbavboa U, Cleary JP, O'Hare EO, Wood WG. Amyloid beta-peptide(1-40) increases neuronal membrane fluidity. Role of cholesterol and brain region. J Lipid Res. 42, 1292-7 (2001) [ PubMed ]; Wood WG, Schroeder F, Igbavboa U, Avdulov NA, Chochina SV. Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiol Aging. 23, 685-94 (2002) [ PubMed ][ Back2Text ].

32. Eroglu S, Brügger B, Wieland F, Sinning I. Glutamate-binding affinity of Drosophila metabotropic glutamate receptor is modulated by association with lipid rafts. Proc Natl Acad Sci USA. 100, 10219-24 (2003) doi:10.1073/pnas.1737042100 [ PubMed ][ Back2Text ].

33. Hering H, Lin C-C, Sheng M. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci. 23, 3262-71 (2003) [ PubMed ][ Back2Text ].

34. Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. Anesthesiology. 96, 202-31 (2002) [ PubMed ][ Back2Text ].

35. Koudinova NV, Koudinov AR. APP and amyloid beta protein are integrated sensor-effector system for neural cholesterol and membrane dynamics regulation. Soc Neurosci Abstr. Program No. 23.8 (2003) [ Abstract ][ Back2Text ].

36. Yamazaki T, Chang TY, Haass C. Accumulation and aggregation of amyloid beta-protein in late endosomes of  Niemann-Pick Type C Cells. J Biol Chem. 276, 4454-60 (2001) [ PubMed ][ Back2Text ].

37. Puglielli L, Konopka G, Pack-Chung E, et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol. 10, 905-12 (2001) [ PubMed ][ Back2Text ].

38. Dufour F, Zhao W-Q, Ravindranath L, Alkon DL. Abnormal cholesterol processing in Alzheimer’s disease patient’s fibroblasts. Neurobiol Lipids.  1, 7 (2003) [ FullText ][ Back2Text ].

39. Bouillot C, Prochiantz A, Rougon G, Allinquant B. Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties. J Biol Chem. 271, 7640-4 (1996) [ PubMed ]; Ikezu T, Trapp BD, Song KS, Schlegel A, Lisanti MP, Okamoto T. Caveolae, plasma membrane microdomains for alpha-secretase-mediated processing of the amyloid precursor protein. J Biol Chem. 273, 10485-95 (1998) [ PubMed ][ Back2Text ].

40. Borroni B, Colciaghi F, Lenzi GL, et al. High cholesterol affects platelet APP processing in controls and in AD patients.
Neurobiol Aging. 24, 631-6 (2003) [ PubMed ][ Back2Text ].

41. Manni ME, Cescato R, Paganetti PA. Lack of b-amyloid production in M19 cells deficient in site 2 processing of the sterol regulatory element binding proteins. FEBS Lett. 427, 367-70 (1998) [ PubMed ][ Back2Text ].

42. Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell. 100, 391-8 (2000) [ PubMed ]; Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 109, 1125-31 (2002) [ PubMed ]; Fielding CJ, Fielding PE. Intracellular cholesterol transport. J Lipid Res. 38, 1503-21 (1997) [ PubMed ][ Back2Text ].

43. Sun Y, Yao J, Kim TW, Tall AR. Expression of LXR target genes decreases cellular amyloid beta peptide secretion. J Biol Chem. 278, 27688-94 (2003) doi: 10.1074/jbc.M300760200 [ PubMed ]; Fukuchi J, Song C, Ko AL, Liao S. Transcriptional regulation of farnesyl pyrophosphate synthase by liver X receptors. Steroids. 68, 685-91 (2003) [ PubMed ][ Back2Text ].

44. Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J. 21, 5691-700 (2002) [ PubMed ][ Back2Text ].

45. Fukumoto H, Deng A, Irizarry MC, Fitzgerald ML, Rebeck WG. Induction of the cholesterol transporter ABCA1 in CNS cells by LXR agonists increases secreted Ab levels. J Biol Chem. 277, 48508-13 (2002) doi: 10.1074 doi: jbc.M209085200 [ PubMed ]. Also see: Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson J-A. Liver X receptors in the central nervous system: From lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci USA. 99, 13878-83 (2002) doi: 10.1073/pnas.172510899 [ PubMed ][ Back2Text ].

46. Tschape J-A, Hammerschmied C, Muhlig-Versen M, Athenstaedt K, Daum G, Kretzschmar D. The neurodegeneration mutant lochrig interferes with cholesterol homeostasis and Appl processing. EMBO J. 21, 6367-76 (2002) [ PubMed ][ Back2Text ].

47. Igbavboa U, Pidcock JM, Johnson LN, et al. Cholesterol distribution in the golgi complex of astrocytes is differentially altered by fresh and aged amyloid b-peptide1-42. J Biol Chem. 278, 17150-7 (2003) doi: 10.1074/jbc.M301150200 [ PubMed ][ Back2Text ].

48. Koldamova RP, Lefterov IM, Ikonomovic MD, et al. 22R-Hydroxycholesterol and 9-cis-retinoic acid induce ABCA1 transporter expression and cholesterol efflux in brain cells and decrease Abeta secretion. J Biol Chem. 278,  13244-56 (2003) doi: 10.1074/jbc.M300044200 [ PubMed ][ Back2Text ].

49. Cupers P, Orlans I, Craessaerts K, Annaert W, De Strooper B. The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture. J Neurochem. 78, 1168-78 (2001) [ PubMed ][ Back2Text ].

50. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to  therapeutics.
Science. 297, 353 (2002) [Erratum in: Science. 297, 2209 (2002)] [ PubMed ] [ Erratum FullText ][ Back2Text ].

51. Koudinov AR. Amyloid was never clearly implicated in Alzheimer's disease, so look at Abeta from a different angle. BMJ.  (30 Nov 2002) [ FullText ][ Back2Text ].

52. Schulz PE. b-peptides enhance the magnitude and probability of long term potentiation. Soc Neurosci Abstr. 22, 2111 (1996) [ Back2Text ].

53. Huber G, Bailly Y, Martin JR, Mariani J, Brugg B. Synaptic b-amyloid precursor proteins increase with learning capacity in rats. Neurosci. 80, 313-20 (1997) [ PubMed ]; Ribaut-Barassin C, Moussaoui S, Brugg B, et al. Hemisynaptic distribution patterns of presenilins and beta-APP isoforms in the rodent cerebellum and hippocampus. Synapse. 35, 96-110 (2000) [ PubMed ][ Back2Text ].

54. Kamenetz F, Tomita T, Hsieh H,  et al. APP processing and synaptic function. Neuron. 37, 925-37 (2003) [ PubMed ]; Kamenetz FR, Tomita T, Borchelt DR, Sisodia SS, Iwatsubo T, Malinow R. Activity dependent secretion of b-amyloid: roles of b-amyloid in synaptic transmission. Soc Neurosci Abstr. 26, 491 (2000) [ FullText ][ Back2Text ].

55. Heese K, Nagai Y, Sawada T. Identification of a new synaptic vesicle protein 2B mRNA transcript which is up-regulated in neurons by amyloid beta peptide fragment (1-42). Biochem Biophys Res Commun. 289, 924-8 (2001). [ PubMed ][ Back2Text ].

56. Lazarov O, Lee M, Peterson DA, Sisodia SS. Evidence that synaptically released b-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci.22, 9785-93 (2002) [ PubMed ][ Correspondence ][ Back2Text ].

57. Isacson O, Lin I. Cholinergic modulation of amyloid processing and dementia in animal models of Alzheimer's disease. Ann NY Acad Sci. 920, 309-14 (2000) [ PubMed ][ Back2Text ]. Also see: Von Der Kammer H, Mayhaus M, Albrecht C, et al. Regulation of gene expression by muscarinic acetylcholine receptors: a comprehensive approach for the identification of regulated genes. Ann NY Acad Sci. 920, 305–8 (2000) [ PubMed ]; Von Der Kammer H, Demiralay C, Andresen B, Albrecht C, Mayhaus M, Nitsch RM. Regulation of gene expression by muscarinic acetylcholine receptors. Biochem Soc Symp. 67, 131-40 (2001) [ PubMed ][ Back2Text ].

58. Hock C, Maddalena A, Heuser I, et al. Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease. Ann N Y Acad Sci. 920, 285-91 (2000) [ PubMed ]; Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH.  The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 48, 913-8 (2000) [ PubMed ][ Back2Text ].

59. Nitsch RM, Deng A, Wurtman RJ, Growdon JH. Metabotropic glutamate receptor subtype mGluR1alpha stimulates the secretion of the amyloid beta protein precursor ectodomain. J Neurochem. 69, 704-12 (1997) [ PubMed ][ Back2Text ].

60. Nitsch RM, Deng M, Growdon JH, Wurtman RJ. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem. 271, 4188-94 (1996) [ PubMed ].

61. Scanlon SM, Williams DC, Schloss P. Membrane cholesterol modulates serotonin transporter activity. Biochem. 40,10507-13 (2001) [ PubMed ][ Back2Text ].

62. Kar S, Seto D, Gaudreau P, Quirion R. b-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. J Neurosci. 16, 1034-40 (1996) [ PubMed ]; Kar S, Issa AM, Seto D, Auld DS, Collier B, Quirion R. Amyloid beta-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J Neurochem. 70, 2179-87 (1998) [ PubMed ][ Back2Text ].

63. Good TA, Smith DO, Murphy RM. b-amyloid peptide blocks the fast-inactivating K+ current in rat hippocampal neurons. Biophys J. 70, 296-304 (1996)  [ PubMed ][ Back2Text ].

64. Blitzer RD, Wong T, Giovannini MG, Pangalos MN, Robakis NK, Landau EM. Amyloid beta peptides activate the phosphoinositide signaling pathway in oocytes expressing rat brain RNA.  Brain Res Mol Brain Res. 76, 115-20 (2000) [ PubMed ][ Back2Text ].

65. Ueda K, Shinohara S, Yagami T, Asakura K, Kawasaki K. Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: a possible involvement of free radicals. J Neurochem. 68, 265-71 (1997) [ PubMed ][ Back2Text ].

66. Lin H, Zhu YWJ. Amyloid beta protein (1-40) (A beta P) reconstituted in lipid vesicles forms calcium-permeable channels. Biophys J. 76, A146 (1999); Lin H, Zhu YJ, Lal R. Amyloid beta protein (1-40) forms calcium-permeable, Zn2+-sensitive channel in reconstituted lipid vesicles. Biochemistry. 38, 11189-96 (1999) [ PubMed ]; Lin H, Bhatia R, Lal R. Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J. 15, 2433-44 (2001) [ Erratum in: FASEB J. 16, 759 (2002)][ PubMed ][ Erratum FullText ][ Back2Text ].

67. Koudinov AR, Berezov TT, Koudinova NV. The levels of soluble Ab in different HDL subfractions distinguish Alzheimer's and normal aging CSF: implication for brain cholesterol pathology? Neurosci Lett. 314, 115-8 (2001) [ PubMed ][ Full Text ][ Back2Text ].

68. Koudinova NV. Alzheimer's amyloid beta oligomers and lipoprotein apoAb: mistaken identity is possible. Bioessays. 25, 1024 (2003) doi: 10.1002/bies.10348 [ PubMed ][ FullText ]; Authors response: Alzheimer vaccine: an update. Bioessays. 25, 1025 (2003) doi: 10.1002/bies.10347 [ PubMed ][ FullText ]; Article under discussion: Robinson SR, Bishop GM, Munch G. Alzheimer vaccine: amyloid b on trial. Bioessays. 25, 283-8 (2003) [ PubMed ][ Back2Text ].

69. Koudinov AR, Berezov TT, Koudinova NV. Alzheimer's amyloid beta and lipid metabolism: a missing link? FASEB J. 12, 1097-9 (1998) [ PubMed ][ Back2Text ].

70. Cedazo-Minguez A, Huttinger M, Cowburn RF. Beta-VLDL protects against Abeta(1-42) and apoE toxicity in human SH-SY5Y neuroblastoma cells. NeuroReport. 12, 201-6 (2001) [ PubMed ][ Back2Text ].

71. Farhangrazi ZS, Ying H, Bu G, et al. High density lipoprotein decreases beta-amyloid toxicity in cortical cell culture. NeuroReport. 8, 1127-30 (1997) [ PubMed ][ Back2Text ].

72. Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits Abeta aggregation and toxicity. Biochemistry. 40, 3553-60 (2001) [ PubMed ][ Back2Text ].

73. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid (protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416, 535-9 (2002) [ PubMed ][ Nature News coverage ], Correspondence: Koudinov AR, Koudinova NV. Amyloid hypothesis, synaptic function, and Alzheimer’s disease, or Beware: the dogma is revitalized. BMJ. (15 May 2002) [ FullText ]; Koudinov AR. Amyloid beta road show, or Has the lure of profits corrupted Alzheimer’s neuroscience? Science's SAGE KE. (5 Aug 2003) [ FullText ][ Back2Text ].

74. Gong Y, Chang L, Viola KL, et al. Alzheimer's disease-affected brain: Presence of oligomeric Abeta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. (18 Aug 2003) doi: 10.1073/pnas.1834302100 [ PubMed ]; Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 95, 6448-53 (1998) [ PubMed ][ Back2Text ].

75. Koudinov AR, Berezov TT, Kumar A, Koudinova NV. Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin Chim Acta. 270, 75-84 (1998) [ PubMed ][ Back2Text ].

76. Wang HW, Pasternak JF, Kuo H, et al. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133-40 (2002) [ PubMed ][ Back2Text ].

77. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA. The production of amyloid-beta peptide is a critical requirement for the viability of central neurons. J Neurosci. 23, 5531-5 (2003) [ PubMed ][ Back2Text ].

78. Koudinova NV, Koudinov AR. Alzheimer's amyloid beta plaques, oligomers and lipoprotein apo Abeta: a case of mistaken identity? Soc Neurosci Abstr. Program No. 407.14 (2003) [ Abstract ][ Back2Text ].

79. Kontush A, Donarski N, Beisiegel U. Resistance of human cerebrospinal fluid to in vitro oxidation is directly related to its amyloid-beta content. Free Radic Res.35, 507-17 (2001) [ PubMed ][ Back2Text ].

80. Koudinov AR, Groner Y, Segal M. Cu/Zn-SOD transgenic mice are impaired in slow onset, long term potentiation. Neurosci Lett. 51, S23 (1998) [ FullText ][ Back2Text ].

81. Berezov TT, Koudinov AR. Is oxidative stress pathway a physiologic modulator for neural plasticity? 13th Meeting of the European Neurological Society Istanbul, Turkey, June 14-18, 2003. Abstract Book. Program No. P685 (2003) [ FullText ]; Koudinov AR, Koudinova NV. Epileptiform excitability in mice hippocampus is triggered by lipid peroxidation (LPO) activation and depends on the Cu/Zn-superoxide dismutase (SOD1) level. 11th Meeting of the European Neurological Society Paris, France, April 21-25, 2003. Abstract Book. Program No. P760 (2001) [ FullText ][ Back2Text ].

82. Xie Z, Sastry BR. Induction of hippocampal long-term potentiation by alpha-tocopherol. Brain Res. 604, 173-9 (1993) [ PubMed ]; Xie Z, Sastry BR. Impairment of long-term potentiation in rats fed with vitamin E-deficient diet. Brain Res. 681, 193-6 (1995) [ PubMed ][ Back2Text ].

83. Gardner A. The Good and Bad of Experimental Alzheimer's Vaccine. Health Scout News (17 March 2003) [ FullText ] This source includes citation of B Thies: "If you look across the spectrum of Alzheimer's investigators, half or more work is on amyloid." ;  Thies B, Truschke E, Morrison-Bogorad M, Hodes RJ. Letter to the editor: Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer's disease. Neurobiol Aging. 20, 247 (1999) [ PubMed ][ FullText ]; Article under discussion: Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the NIA working group: consensus report of the working group on: "molecular and biochemical markers of Alzheimer's disease. Neurobiol Aging. 19, 109-16 (1998) [Erratum in: Neurobiol Aging. 19, 285 (1998)] [ PubMed][ Erratum FullText ][ Back2Text ].

84. Koudinov AR. Amyloid beta road show, or Has the lure of profits corrupted Alzheimer’s neuroscience? Science's SAGE KE (originally published 5 August 2003)  [ FullText ]; Koudinov AR. Alzheimer's disease vaccine danger: take it straightforward, not double-edged. BMJ (22 Mar 2003) [ FullText ]; Koudinov AR, Koudinova NV. Amyloid hypothesis: summer 2002 and 8th International Conference on Alzheimer’s disease update. BMJ (30 July 2002) [ FullText ][ Back2Text ]; 2002 Research Overview: amyloid hypothesis. Alzheimer's association Official Web site. [ FullText ].

85. Koudinov AR. Open letter to Donald Kennedy: AAAS, Science, Alzheimer’s disease and academic dishonesty. Science's  SAGE KE. (16 June 2003) [ Reprint ]; Koudinov AR. Hasta la vista, amyloid cascade hypothesis, OR will academic dishonesty yield Alzheimer's cure? Science's SAGE KE (26 May 2003) [ FullText ]; Koudinov AR. Open letter to Public Citizen's Health Research Group on Alzheimer's disease research. BMJ online. (27 Feb. 2003) [ FullText ]; Science's SAGE KE (21 Feb. 2003) [ FullText ].

86. Chen QS, Kagan BL, Hirakura Y, Xie C-W (2000) Impairment of hippocampal long-term potentiation by Alzheimer's amyloid b-peptides. J Neurosci Res. 60, 65-72 (2000) [ PubMed ][ Back2Text ].

87. Cullen WK, Wu J, Anwyl R, Rowan, M. (1996) b-Amyloid produces a delayed NMDA receptor-dependent reduction in synaptic transmission in rat hippocampus. NeuroReport. 8, 87-92 (1996) [ PubMed ][ Back2Text ].

88. Freir DB, Holscher C, Herron CE. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J Neurophysiol. 85, 708-13 (2001) [ PubMed ][ Back2Text ].

89. Itoh A, Akaike T, Sokabe M, et al. Impairments of long-term potentiation in hippocampal slices of beta-amyloid-infused rats. Eur J Pharmacol. 382, 167-75 (1999) [ PubMed ][ Back2Text ].

90. Trubetskaya VV, Stepanichev MY, Onufriev MV, Lazareva NA, Markevich VA, Gulyaeva NV. Administration of aggregated beta-amyloid peptide (25-35) induces changes in long-term potentiation in the hippocampus in vivo. Neurosci Behav Physiol. 33, 95-8 (2003) [ PubMed ][ Back2Text ].

91. McDonald M, Cleary PW, Mantyh PW, Dahl E, Overmier JB, Wood G. Effects of acute and chronic beta-amyloid protein (bA4) on memory. Soc Neurosci Abstr. 19, 20 (1993); McDonald MP, Dahl EE, Overmier JB, Mantyh P, Cleary J. Effects of an exogenous beta-amyloid peptide on retention for spatial learning. Behav Neural Biol. 62, 60-7 (1994) [ PubMed ][ Back2Text ].

92. Sweeney WA, Luedtke J, McDonald MP, Overmier JB. Intrahippocampal injections of exogenous b-amyloid induce postdelay errors in an eight-arm radial maze. Neurobiol Learn Mem. 68, 97-101 (1997) [ PubMed ][ Back2Text ].

93. Malin DH, Crothers MK, Lake JR, et al. Hippocampal injections of amyloid beta-peptide 1-40 impair subsequent one-trial/day reward learning. Neurobiol Learn Mem. 76, 125-37 (2001) [ PubMed ][ Back2Text ].

94. Raymond CR, Ireland DR, Abraham WC. NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus. Brain Res. 968, 263-72 (2003) [ PubMed ][ Back2Text ].

95. Chen G, Chen KS, Knox J, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 408, 975-9 (2000) [ PubMed ][ Back2Text ].

96. Stephan A, Laroche S, Davis S. Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J Neurosci. 21, 5703-14 (2001) [ PubMed ][ Back2Text ].

97. Kim JH, Anwyl R, Suh YH, Djamgoz MB, Rowan MJ. Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J Neurosci. 21, 1327-33 (2001) [ PubMed ][ Back2Text ].

98. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 300, 486-9 (2003) [ PubMed ]; Correspondence: Koudinov AR. Alzheimer's amyloid beta oligomers versus lipoprotein Abeta. Science SAGE KE. (1 May 2003) [ FullText ][ Back2Text ].

99. Fitzjohn SM, Morton RA, Kuenzi F, et al. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J Neurosci. 21, 4691-8 (2001) [ PubMed ][ Back2Text ].

100. Darragh B. Freir, Derek A. Costello, Caroline E. Herron. Abeta25-35 induced depression of long-term potentiation in area CA1 in vivo and in vitro is attenuated by verapamil. J Neurophysiol.89, 3061-9 (2003) doi: 10.1152/jn.00992.2002 [ PubMed ][ Back2Text ].

101. Chen QS, Wei WZ, Shimahara T, Xie CW. Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol Learn Mem. 77, 354-71 (2002) [ PubMed ][ Back2Text ].

102. Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA. 99, 13217-21 (2002) [ PubMed ][ Back2Text ].

103. Freir DB, Herron CE. Nicotine enhances the depressive actions of Abeta1-40 on long-term potentiation in the rat hippocampal CA1 region in vivo. J Neurophysiol. 89, 2917-22 (2003) doi: 10.1152/jn.00996.2002 [ PubMed ][ Back2Text ].

104. Nakagami Y, Oda T. Glutamate exacerbates amyloid beta1-42-induced impairment of long-term potentiation in rat hippocampal slices. Jpn J Pharmacol. 88, 223-6 (2002) [ PubMed ][ Back2Text ].

105. Klimov AN, Nikulcheva NG. Metabolism of cholesterol. In: Lipids, Lipoproteins and atherosclerosis. Piter Press, St. Petersburg (1994) pp. 60-70 [ Back2Text ].

106. Cholesterol Biosynthesis 1. The Metabolic Pathways of Biochemistry Web site.  (Last accessed 7 Sept. 2003) [ FullText ][ Related Web Resource ][ Back2Text ].

107. McKenney JM. Pharmacologic characteristics of statins. Clin Cardiol. 26(4 Suppl 3), III32-8 (2003) [ PubMed ]; Gotto AM Jr. Risks and benefits of continued aggressive statin therapy. Clin Cardiol. 26(4 Suppl 3), III3-12[ PubMed ][ Back2Text ].

108. Thompson RB. Foundations for blockbuster drugs in federally sponsored research. FASEB J. 15, 1671-6 (2001) [ PubMed ][ Back2Text ].

109. Chemical structure for: Lipitor (Atorvastatin) [ FullText ]; Cerivastatin (Oral) [ FullText ]; Fluvastatin (Oral)/Lescol® [ FullText ][ Back2Text ].

110. Noonan D. Cholesterol - And Beyond. Newsweek  (14 July 2003; International edition: 28 July 2003) [ FullText ][ Back2Text ].

111. HMG-CoA Reductase Inhibitors (Systemic). NIH  Medline plus health info. [ FullText ][ Back2Text ].

112. Baycoll Litigations. Baycol Litigation.Com Web site. (Last accessed 7 Sept 2003) [ FullText ][ Back2Text ].

113. Kind AH, Zakowski LJ, McBride PE. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction. WMJ.101, 53-6 (2002) [ PubMed ][ Back2Text ].

114. Gaist D, Jeppesen U, Andersen M, García Rodríguez LA, Hallas J,  Sindrup SH. Statins and risk of polyneuropathy. A case-control study. Neurology.58, 1333-7 (2002) [ PubMed ]; Commentary: Donaghy M. Assessing the risk of drug-induced neurologic disorders: Statins and neuropathy. Neurology. 58, 1321-2 (2002) [ PubMed ][ Back2Text ].

115. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 23, 871-80 (2003) [ PubMed ][ Back2Text ].

116. Fassbender K, Stroick M, Bertsch T, et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology.59, 1257-58 (2002) [ PubMed ]; Tokuda T, Tamaoka A, Sakurai S, et al. Plasma levels of amyloid beta protein did not differ between subjects taking statins and not taking statins. Ann. Neurol.49, 546-7 (2001) [ PubMed ][ Back2Text ].

117. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 356, 1627-31 (2000) [ PubMed ]; Erratum in: Lancet. 357, 562 (2001) [ FullText ]; Correspondence: Birkenhager WH, Wang Ji-G, Staessen JA. ; Cheung BMY , Kumana CR ; Blauw GJ, Shepherd J, Murphy MB for the PROSPER study group ; Kast RE ; Lowe G, Rumley A, Packard C, Shepherd J ; Ebrahim S, Shlomo YB, Smith GD, Whincup P, Emberson J. Dementia and statins. Lancet.357, 880 (2001) [ FullText ];  Koudinov AR, Koudinova NV. Dementia, cholesterol and the soft science of dietary fat. BMJ (25 July 2001) [ FullText ][ Back2Text ].

118. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 57, 1439-43 (2000) [ PubMed ][ Author Patent ][ Correpondence ][ Back2Text ].

119. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 52, 346-50 (2002) [ PubMed ][ Back2Text ].

120. Sparks DL, Connor DJ, Browne PJ, Lopez JE, Sabbagh MN. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. J Nutr Health Aging.6, 324-31 (2002) [ PubMed ][ Back2Text ].

121. Bonetta L. Potential neurological value of statins increases. Nat Med. 8, 541 (2002) [ PubMed ][ Back2Text ].

122. Wolozin B, inventor; Nymox Corporation, assignee. Methods for treating, preventing, and reducing the risk of the onset of Alzheimer's disease using an HMG CoA reductase inhibitor. US Patent  6,472,421. 2002 October 29 [ USPTO Record ][ NoL Patent page ][ Back2Text ];

123. Yankner BA, inventor; Children's Medical Center Corporation (Boston, MA), assignee. Methods for determining risk of Alzheimer's disease. US Patent 6,440,387. 2002 August 27 [ USPTO Record ][ NoL Patent page ][ Back2Text ].

124. Principal Investigators: Sano M, Thal LJ; Condition: Alzheimer Disease; Statin at use: simvastatin; Sponsor: NIA; Start date: Dec. 2002. Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study [ FullText ]; Principal Investigator: N/A; Condition: Alzheimer Disease; Statin at use: lovastatin; Sponsor: NIMH; Start date: 2002 Sept 18. The Effect of Short-Term Statin and NSAID Treatment on CSF Beta-amyloid [ FullText]; Principal Investigator: Sparks DL; Condition: Alzheimer Disease; Sponsor: ISOA; Dates: 2001-2006. Is Elevated Serum Cholesterol Predictive of Developing Alzheimer’s Disease: Ancillary Trial to the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) [ FullText ]; Principal Investigator: Sparks DL; Condition: Alzheimer Disease; Statin at use: Lipitor® (Atorvastatin); Sponsor: ISOA, Pfizer; Dates: 2000-2003. A Phase II Trial Investigating the Effect of the Anti-Cholesterol Drug Lipitor® in the Treatment of Alzheimer's Disease [ FullText ]; Drugs in Clinical trials: Statins. AlzForum Web site. (Last accessed: 7 Sept. 2003) [ FullText ][ Back2Text ].
Please note: all links provide no registration free access to documents

fr1. Gateway page for the authors 33rd Society for Neuroscience Annual Meeting 2003 sessions:

Drs. Koudinov Neuroscience 2003 Meeting Central. Dr. Koudinov Internet Office [FullText][Koudinov SFN 2002 gateway][Koudinov SFN 2001/2000 gateway].

fr2.Society for Neuroscience invited press book 2001 Lay language article for:

Koudinova NV, Koudinov AR. Essential Role for Cholesterol in Synaptic Plasticity and Neuronal Degeneration. Soc Neurosci Abst 27, 752.5 (2001) [Lay article fulltext][Abstract][Presentation slide show][Koudinov SFN 2001 gateway].

fr3.Society for Neuroscience invited press book 2001 Lay language article for:

Koudinov AR, Koudinova NV. (2001) Neuronal Cholesterol Pathology is the Cause of Alzheimer's Disease. Soc Neurosci Abst 27, 23.3 (2001) [Lay article fulltext][Abstract][Koudinov SFN 2001 gateway].

fr4.Society for Neuroscience invited press book 2001 Lay language article for:

Koudinov AR, Berezov TT, Koudinova NV. Brain Cholesterol and neuronal function? Soc Neurosci Abst 27, 23.4 (2001) [Lay article fulltext][Abstract][Koudinov SFN 2001 gateway].

fr5.Society for Neuroscience invited press book 2000 Lay language article for:

Koudinov AR, Koudinova NV. Modulation of Cholesterol Metabolism initiates Alzheimer’s Amyloid deposition and Neuronal Dysfunction. Soc Neurosci Abst 26 (1), 497 (2000) [Lay article fulltext][Abstract][Koudinov SFN 2001 gateway].

fr6. Koudinov AR, Koudinova NV, Beisiegel U. Cholesterol homeostasis failure at neuromuscular junctions and CNS synapses: a unifying cause of synaptic degeneration? Neurology (26 Feb 2002) [FullText].

fr7.Koudinov AR, Koudinova NV. Is neurodegeneration a unique multifarious human brain disease? British Medical Journal (23 June 2002) [FullText][Essential supplement].

fr8. Current hypotheses. AlzForum web site. (last updated 21 Aug 2003) [FullText].

fr9. Teter B, Ashford JW.Neuroplasticity in Alzheimer's disease. J Neurosci Res. 70, 402-37 (2002). [PubMed].

fr10. Koudinova NV, Kontush A, Berezov TT, Koudinov AR. Amyloid beta, neural lipids, cholesterol and Alzheimer's disease. Neurobiol Lipids. 1, 6 (2003) [FullText].

Also see:

Goldman B. Alzheimer's Disease: The tangled challenge. Signals magazine(3 Dec 1998) [FullText].

Live discussion "Cholesterol and Alzheimer's disease". Held 19 Nov 2002. AlzForum web site [Transcipt].

Current hypotheses. AlzForum web site. (last updated 21 August 2003) [ FullText ].

Authors' web site: http://koudinov.info .

Koudinov AR. Does Rotterdam study question the link between fat and dementia? Neurology online (15 Jan 2003) [FullText].

Koudinov AR, Koudinova NV. Dementia, cholesterol and the soft science of dietary fat. BMJ online (27 July 2001) [FullText].

Koudinov AR, Koudinova NV. Alzheimer's pathogenesis: tau and amyloid - a consensus or a challenge for a third party quest? BMJ online (4 Sept 2001) [FullText].

Koudinov AR, Berezov TT, Koudinova NV. High density lipoproteins as hidden imprint of Alzheimer's brain cholesterol pathology. Neurology (12 Dec 2001) [FullText]

Koudinov AR, Berezov TT, Koudinova NV. Genetics/cardiovascular risk versus environment/Alzheimer's: directions diverted, cholesterol united. BMJ (14 Dec 2001) [FullText

Noteworthy articles on neurobiology of lipids. Neurobiol lipids. [Noteworthy page].

Patents on neurobiology of lipids. Neurobiol lipids. [Patents page]

This article should be cited in the following way

Koudinov AR, Koudinova NV. Amyloid beta protein restores hippocampal long term potentiation: a central role for cholesterol? Neurobiol. Lipids  Vol.1, 8 (2003), Published online September 15, 2003, Available at: http://neurobiologyoflipids.org/content/1/8/
( Provide web address when citing this paper )
Please note: Because Neurobiology of Lipids is published online only, the articles should be cited with an article number rather than with traditional (printed) page numbers. Acrobat (.PDF) reprints of NoL article, however,  serve the algorithmic needs of tenure committees to count published print pages.

CACorresponding author: Alexei Koudinov, M.D., Ph.D., c/o P.O. Box 1665, Rehovot 76100, Israel ; e-mail: koudin@med.pfu.edu.ru ; URL: http://koudinov.info

#Footnote 1: Prior to the 32nd Society for Neuroscience Meeting (Orlando, Nov. 2-7, 2002) Neurobiology of Lipids published the editorial (2002, Vol.1, 5) that compiled the abstracts on the subject of the journal scope. Neurobiology of Lipids editors were invited to select the most noteworthy abstracts from the list of more then two hundered presentations. The short list yielded eighteen presentations. The authors of these presentations were invited to publish in NoL proceedings articles matching the content of the SFN 2002 presentations. This article represents the one of six silver choice presentations. The acceptance date represents the day of the article appearence at the 32nd SFN Annual Meeting in Orlando, Florida, Nov 2-7, 2002.

To review other neurobiology of lipids SFN Annual Meeting abstracts 2002 and the editors' choice shortlist please click here.

§Footnote 2: The presented proceedings article is based on the scientific session presented on 7 November 2002 at the 32nd Society for Neuroscience Annual Meeting 2002 in Orlando, Florida. To cite original SFN abstract use: 

Koudinov AR, Koudinova NV. Amyloid beta protein restores hippocampal long term potentiation: a central role for cholesterol? Soc Neurosci Abstr online. Program No.884.1 Published online 23 Sept. 2002. [ 32nd SFN NoL abstracts ][ Abstract at ScholarOne ][ Authors other SFN 2002 abstracts ].

This article has been cited by other articles:

Restorative Neurology and Neuroscience
Heese K, Inoue N, Nagai Y, Sawada T.
APP, NGF & the 'Sunday-driver' in a Trolley on the Road.
Restor Neurol Neurosci. 22(2), 131-136 (2004)
[ PubMed ]

Acta Neurobiologiae Experimentalis
Koudinov AR, Berezov TT.
Alzheimer's amyloid beta (Ab) is an essential synaptic protein, not neurotoxic junk.
Acta Neurobiol Exp. 64, 71-79 (February 2004)
[ PubMed ][ Free Access PDF. FullText ]

Koudinov AR, Koudinova NV.
Cholesterol, synaptic function and Alzheimer's disease.
Pharmacopsych. 36, S107-112 (October 2003)
[ PubMed ]

Drugs Aging
Bishop GM, Robinson SR.
Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease.
Drugs Aging. 21(10), 621-630 (2004)
[ PubMed ]

Journal of the Neurological Sciences
Koudinov AR, Koudinova NV.
Cholesterol homeostasis failure as a unifying cause of synaptic degeneration.
J Neurol Sci. doi:10.1016/j.jns.2004.11.036 (16 December 2004)
[ PubMed ][ Summary ][ FullText ][ PDF ]

Journal of Chemical Neuroanatomy
Gonzalo-Ruiz A, Sanz JM, Arevalo J, Geula C, Gonzalo P.
Amyloid beta peptide-induced cholinergic fibres loss in the cerebral cortex of the rat is modified by diet high in lipids and by age.
J Chem Neuroanat. 29(1), 31-48 (January 2005)
[ PubMed ]

PLOS Medicine
Koudinov AR, Berezov TT.
Cholesterol, Statins, and Alzheimer's disease.
PLOS Medicine. (24 January 2005)
[ ePub FullText ]

Copyright © 2002, 2003 by the Neurobiology of Lipids, ISSN 1683-5506   Locations of visitors to this page